Skip to content

Evaluating Effectiveness of Elevated Intra-abdominal Pressure (IAP) by PressureDOT

Evaluating Effectiveness of Elevated Intra-abdominal Pressure (IAP) by PressureDOT

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06709924
Acronym
IAP
Enrollment
20
Registered
2024-11-29
Start date
2024-11-25
Completion date
2024-12-06
Last updated
2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraabdominal Pressure

Keywords

Intraabdominal pressure, capsule

Brief summary

To test the diagnostic efficacy of using the PressureDOT, an in-body real-time pressure-sensing smart capsule, in monitoring elevated intra-abdominal pressure in subjects. This study aims to evaluate the PressureDOT (abbreviated as PDT, serial number: PD01), a state-of- the-art continuous pressure sensing system that is among the most advanced in the world. Unlike traditional methods of monitoring intra-abdominal pressure, such as indirectly measuring abdominal pressure by infusing saline into the bladder, PDT offers a minimally invasive, wireless solution intended to reduce the common risk of urinary tract infections associated with traditional methods and significantly decrease the need for manual operations. The PDT capsule utilizes high-density circuit board technology and is protected by a unibody encapsulation that shields its internal components. This design enables the capsule to precisely and continuously monitor intra-abdominal pressure and temperature while transmitting data to an external receiving device wirelessly. Additionally, the external receiver is equipped with a special algorithm that can instantly track the capsule's speed of movement through the gastrointestinal tract, providing richer data support for clinical diagnosis. Considering that elevated intra-abdominal pressure is a potential early high-risk factor for various diseases and closely related to the user's health status, this project plans to conduct a Phase I clinical trial across a broad spectrum of groups, including athletes, astronauts, vocalists, individuals undergoing rehabilitation, and any participants at risk of increased intra-abdominal pressure. These groups may face a risk of elevated intra-abdominal pressure due to their unique circumstances. Through this clinical trial, we hope to validate the effectiveness of PDT in the early diagnosis of elevated intra-abdominal pressure, reduce the long-term risk of exposure to high intra-abdominal pressure for participants, and further alleviate the burden on medical practitioners, thereby reducing medical costs.

Interventions

OTHEREXERCISE TRAINING WITHOUT MEDICATION

After ingesting the capsular sensor, the participants were request to perform exercise packages and monitor the change of signal transmission rate and shift of intraabdominal pressure level.

Sponsors

China Medical University Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Months to 65 Months
Healthy volunteers
Yes

Inclusion criteria

* healthy participants without previous surgical history

Exclusion criteria

* previous abdominal surgical history * GI obstruction history * no need of magnetic resonance imaging in two weeks after capsule ingestion. * history of swallowing difficulty, dysphagia, odynophagia.

Design outcomes

Primary

MeasureTime frameDescription
Safety passage of capsule7daysmonitor the passage rate of each participants and evaluate the risk for capsule retained rate.

Secondary

MeasureTime frameDescription
Signal transmission of capsule2 daysThe pressure monitoring data transmission rate. We will collect all the signals from participants and calculate the data lost rate.
Intraandominal pressure monitoring2 daysThe intraabdominal pressure were record when the capsule stay in the participants' body

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026